CAMBRIDGE, Mass., Sept. 16, 2011 /PRNewswire/ — Pathfinder Cell
Therapy, Inc. (“Pathfinder”)(OTCQB: PFND), a biotechnology company
focused on the treatment of diseases characterized by
organ-specific cell damage, today announced that effective at the
start of trading today, the ticker symbol for its common stock will
change from SYMD to PFND. The new ticker symbol follows the
recent change of the company’s name and has been approved by the
Financial Industry Regulatory Authority.
About Pathfinder Cell Therapy, Inc.
Pathfinder is developing a novel cell-based therapy with the
potential to transform the treatment of diabetes, renal disease,
myocardial infarction, and other diseases characterized by
organ-specific cell damage. Leveraging its internal discovery
of Pathfinder
Cells (“PCs”) and a proprietary means of isolating these cells
from surrounding tissue, Pathfinder is pioneering a new field in
regenerative medicine. PCs are a newly identified mammalian
cell type present in very low quantities in a variety of different
organs, including the kidney, liver, pancreas, lymph nodes, and
other tissues.
Early studies indicate that PCs stimulate regeneration of
damaged tissues without the cells themselves being incorporated
into the new tissue. The cells appear to be “immune
privileged,” and their effects are independent of the tissue source
of PCs. PCs isolated from both rat and human tissue sources
have shown efficacy in animal models of diabetes, cardiac ischemia
and renal reperfusion injury.
For more information please visit: www.pathfindercelltherapy.com
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements. You
should be aware that our actual results could differ materially
from those contained in the forward-looking statements, which
ar
‘/>”/>
SOURCE